Organizations reacted this week to news that CMS is raising Part B premiums with a variety of opinions, as CMS blamed rising drug prices for the increase.
Organizations reacted this week to news that CMS is raising Part B premiums with a variety of opinions, as CMS blamed rising drug prices for the increase.
“The increase in the Part B premiums and deductible is largely due to rising spending on physician-administered drugs,” CMS said last week. “These higher costs have a ripple effect and result in higher Part B premiums and deductible.”
Yearly adjustments to all parts of Medicare are made according to the Social Security Act. For 2020, the new costs for most beneficiaries are:
The majority of beneficiaries (70%) pay the standard amount; a minority of upper-income beneficiaries pay more. However, the standard increase for Part B in 2019 was much more modest ($1.50); in addition, the CMS announcement follows a small (1.6%) cost-of-living adjustment to 2020 benefits in 2020, which was pointed out by the AARP.
“This announcement is another clear example of how prescription drug prices are rising faster than inflation and how drug company greed is hurting seniors. With Medicare premiums increasing nearly 7% while Social Security payments will increase less than 2%, Congress needs to immediately act to lower prescription drug prices,” said Nancy LeaMond, AARP’s executive vice president and chief advocacy and engagement officer.
The Biosimilars Forum also chimed in, criticizing Congress and the administration for not doing enough to increase access to biosimilars, saying that the 9 biosimilars available in Part B cost about 30% less than the reference products. They said that beneficiaries “are often denied access to or unaware a lower-cost option exists due to misaligned incentives that favor the higher-cost product.”
The forum, which represents 8 biosimilar developers, has been advocating for ending out-of-pocket cost for biosimilars, saying such a move could save as much as $3.3 billion and increase access. In the statement, the forum highlighted 3 bipartisan bills that have been introduced in Congress:
The BIOSIM act is also included in the drug pricing plan preferred by House Speaker Nancy Pelosi, D-California, although it will not be considered by the Senate, even as seriously ill beneficiaries continue to struggle with healthcare costs. Meanwhile, President Trump is said to prefer a bipartisan Senate bill, but that does not have unanimous Republican support either.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.